CureSearch

Home » Archives for CureSearch

CureSearch and UK-based LifeArc to Co-fund Nearly $1.5M in High-grade Glioma Research

We’re partnering internationally to create far-reaching impact for kids with cancer We’re excited to share news of our recent partnership with LifeArc, a highly-regarded UK-based medical research charity. LifeArc will co-fund Dr. Gregory Friedman’s CureSearch Acceleration Initiative (AI) project aimed […]

CureSearch and UK-based LifeArc to Co-fund Nearly $1.5M in High-grade Glioma Research Read More »

Dr. Gregory Friedman blog

FDA Grants Approval of New Pediatric Glioma Drug to Day One, a Biopharma Co-founded by CureSearch Board Member Dr. Samuel Blackman

Pediatric low-grade glioma (pLGG) is the most common form of pediatric brain cancer. Day One’s OJEMDA™ is the first targeted treatment for pLGG tumors with BRAF fusions and mutations. Last week, on April 23, 2024, Day One Biopharmaceuticals was granted Accelerated

FDA Grants Approval of New Pediatric Glioma Drug to Day One, a Biopharma Co-founded by CureSearch Board Member Dr. Samuel Blackman Read More »

High-risk neuroblastoma in children has a grim outlook. Dr. Jonus is fighting to change that.

Neuroblastoma is the most common extracranial solid tumor of childhood arising within the developing nervous system. Approximately half of neuroblastoma patients are diagnosed with high-risk disease, which is especially aggressive with a 50% survival rate. If a child’s high-risk neuroblastoma

High-risk neuroblastoma in children has a grim outlook. Dr. Jonus is fighting to change that. Read More »

Dr. Hunter Jonus

Pin It on Pinterest

Scroll to Top